Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | GFER | P55789 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | HTR1A | P08908 | 7/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7932173 | 0.98 | KMT2A (0.73) | KMT2AALDH1A1GFERMAPTHTR1A | |
| SCHEMBL31093108 | 0.94 | KMT2A (0.74) | KMT2AALDH1A1GFERMAPTHTR1A | |
| SCHEMBL16026463 | 0.93 | KMT2A (0.83) | KMT2AALDH1A1GFERMAPTHTR1A | |
| Hydrochloric Acid SCHEMBL7934846 | 0.91 | KMT2A (0.83) | KMT2AALDH1A1GFERMAPTHTR1A | |
| SCHEMBL17549676 | 0.88 | KMT2A (0.71) | KMT2AALDH1A1GFERMAPTHTR1A | |
| SCHEMBL17549664 | 0.88 | KMT2A (0.71) | KMT2AALDH1A1GFERMAPTHTR1A | |
| Hydrochloric Acid SCHEMBL8344861 | 0.87 | KMT2A (0.71) | KMT2AALDH1A1GFERMAPTHTR1A | |
| SCHEMBL2725965 | 0.86 | KMT2A (0.90) | KMT2AALDH1A1GFERMAPTHTR1A | |
| SCHEMBL10507206 | 0.86 | ALDH1A1 (0.96) | KMT2AALDH1A1GFERMAPTHTR1A | |
| Hydrochloric Acid SCHEMBL7929082 | 0.85 | THRA (0.60) | KMT2AALDH1A1GFERMAPTHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542687-A1 | SMALL ORGANIC MOLECULES THAT INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB INCORPORATED (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2004028538-A1 | SMALL ORGANIC MOLECULES THAT INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB INCORPORATED (US) | 2004-04-08 | — | — | WO | claimed |
| US-20040068017-A1 | Small organic molecules that increase the activity of Gelatinase A in ocular cells | BAUSCH & LOMB INCORPORATED | 2004-04-08 | — | — | US | claimed |
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2016-03-03 | — | — | US | disclosed |
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2016-03-03 | — | — | US | disclosed |
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PHARMACYCLICS INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-8937091-B2 | Inhibitor of protein crosslinking and use of the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2015-01-20 | — | — | US | disclosed |
| US-8937091-B2 | Inhibitor of protein crosslinking and use of the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
| US-8524744-B2 | preventing and/or treating the diseases related to the plaque-activating factors, especially in anti-inflammation and immunization, more especially in the treatment of the acute or chronic inflammation, such as, osteoarthritis, oarthritis deformans, etc. | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-09-03 | — | — | US | disclosed |
| US-20120277423-A1 | PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME | JAPAN SCIENCE AND TECHNOLOGY AGENCY | 2012-11-01 | — | — | US | disclosed |
| EP-1901744-A2 | PREPARATIONS COMPRISING ARYLAZINE SUBSTITUTED WITH A CARBONYLIC MOIETY TO INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB INCORPORATED (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070293499-A1 | Intracellular Kinase Inhibitors | MANNKIND CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070049559-A1 | Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of Gelatinase A in ocular cells | BAUSCH & LOMB INCORPORATED | 2007-03-01 | — | — | US | disclosed |
| WO-2007002781-A2 | PREPARATIONS COMPRISING ARYLAZINE SUBSTITUTED WITH A CARBONYLIC MOIETY TO INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB INCORPORATED (US) | 2007-01-04 | — | — | WO | disclosed |
| US-7071211-B2 | Small organic molecules that increase the activity of gelatinase a in ocular cells | BAUSCH & LOMB INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060121090-A1 | Ocular compositions that increases the activity of gelatinase a in ocular cells | BAUSCH & LOMB INCORPORATED | 2006-06-08 | — | — | US | disclosed |
| EP-1542687-A1 | SMALL ORGANIC MOLECULES THAT INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB INCORPORATED (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004028538-A1 | SMALL ORGANIC MOLECULES THAT INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB INCORPORATED (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040068017-A1 | Small organic molecules that increase the activity of Gelatinase A in ocular cells | BAUSCH & LOMB INCORPORATED | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293499-A1 | Intracellular Kinase Inhibitors | PI4KB, BTK, LTK | KMT2A 1458/4885ALDH1A1 4370/4885GFER 4667/4885 |
| US-20060121090-A1 | Ocular compositions that increases the activity of gelatinase a in ocular cells | MMP3, MMP13, MMP1 | KMT2A 4410/4885ALDH1A1 1253/4885GFER 3284/4885 |
| US-20040068017-A1 | Small organic molecules that increase the activity of Gelatinase A in ocular cells | MMP1, MMP3, MMP10 | KMT2A 4221/4885ALDH1A1 789/4885GFER 2372/4885 |
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | KMT2A 1458/4885ALDH1A1 4370/4885GFER 4667/4885 |
| US-20070049559-A1 | Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of Gelatinase A in ocular cells | MMP1, MMP17, MMP15 | KMT2A 1982/4885ALDH1A1 333/4885GFER 1295/4885 |
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | RNASE1, CDKL2, CDKL1 | KMT2A 903/4885ALDH1A1 3775/4885GFER 4671/4885 |
| US-20120277423-A1 | PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME | ARGLU1, F12, CDKL1 | KMT2A 2055/4885ALDH1A1 2990/4885GFER 406/4885 |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | KMT2A 1458/4885ALDH1A1 4370/4885GFER 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.